DWA
CCCC icon

Douglass Winthrop Advisors’s C4 Therapeutics CCCC Stock Holding History

Douglass Winthrop Advisors’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-14,014
Closed -$340K – 260
2022
Q1 		$340K Hold
14,014
– – 0.01% 223
2021
Q4 		$451K Hold
14,014
– – 0.01% 205
2021
Q3 		$626K Hold
14,014
– – 0.02% 173
2021
Q2 		$530K Buy
+14,014
New +$502K 0.01% 190

Other funds holding CCCC

ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Douglass Winthrop Advisors's CCCC Position: Q2 2022 in Review

Douglass Winthrop Advisors sold out of C4 Therapeutics (CCCC) in Q2 2022, closing a stake of 14,014 shares — an estimated $340K sold.

Douglass Winthrop Advisors first reported a position in CCCC in Q2 2021 and held it in 4 quarters. The position peaked at $626K in Q3 2021. 113 funds tracked by Wall St. Rank hold CCCC as of Q2 2022.

  • Douglass Winthrop Advisors reported no remaining C4 Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Douglass Winthrop Advisors sold 14,014 C4 Therapeutics shares in Q2 2022, an estimated $340K.
  • Douglass Winthrop Advisors first reported a position in C4 Therapeutics in Q2 2021 and held it in 4 quarters.
  • Douglass Winthrop Advisors's C4 Therapeutics position peaked at $626K in Q3 2021.
  • 113 funds tracked by Wall St. Rank held C4 Therapeutics as of Q2 2022.

Based on Douglass Winthrop Advisors's 13F filing for Q2 2022, filed 11 Aug 2022.